Aspyrian Therapeutics, Inc., a biotechnology company developing precision-targeted cancer therapies based on the proprietary Photoimmunotherapy (PIT) platform, today announced that findings from an ongoing clinical trial of its proprietary investigational compound, RM-1929, were presented at the American Head & Neck Society meeting, April 27, in San Diego…click here to continue reading